Proposal for Alda-1

Overview of Therapeutic Candidate:
Alda-1 is a synthetic small molecule that was discovered through systematic drug discovery efforts aimed at identifying compounds capable of allosterically activating mitochondrial aldehyde dehydrogenase 2 (ALDH2). Unlike classical competitive inhibitors or substrates, Alda-1 binds at a unique allosteric site located near the substrate entrance of ALDH2, thereby serving as a structural chaperone that stabilizes the enzyme’s active conformation. This binding not only protects critical cysteine residues from inactivation by reactive aldehydes but also promotes improved interaction with the NAD⁺ cofactor, ultimately accelerating the catalytic oxidation of hazardous aldehydes such as acetaldehyde and the lipid peroxidation product 4-hydroxy-2-nonenal (4-HNE) (Kimura, Yokoyama, & Higuchi, 2019; Gao, Hao, Piao, & Gu, 2022). Alda-1 belongs to a novel class of ALDH2 activators that have been the subject of extensive preclinical investigation for their cardioprotective and neuroprotective properties in models of ischemia/reperfusion injury, neurodegeneration, and inflammatory conditions. Mechanistically, the discovery and optimization of this compound have been guided by structure–activity relationship studies which delineated how the chemical structure of Alda-1 supports its ability to modulate ALDH2 activity allosterically. This chemical class is drawing considerable attention because by enhancing the intrinsic capacity of ALDH2 to detoxify reactive aldehydes, these molecules directly address the toxicity that arises from oxidative stress in numerous tissues (Kimura et al., 2019; Gao et al., 2022; Long et al., 2020).

Therapeutic History:
Historically, Alda-1 has been evaluated in a broad spectrum of experimental models characterized by high levels of oxidative stress and lipid peroxidation. In cardiovascular research, Alda-1 administration in animal models of ischemia/reperfusion injury has yielded robust cardioprotective effects by reducing the accumulation of toxic aldehydes such as 4-HNE, thereby preventing mitochondrial dysfunction, preserving myocardial tissue architecture, and improving overall cardiac performance (Kimura et al., 2019). In hepatic models of ischemia/reperfusion injury, preclinical studies demonstrated that Alda-1 reduced liver enzyme release and histological injury markers, supporting its role in diminishing oxidative damage through enhanced aldehyde detoxification (Zhang et al., 2018). Neuroprotective studies have similarly employed Alda-1 in models of experimental autoimmune encephalomyelitis and other neurodegenerative conditions, finding a decrease in reactive aldehyde accumulation, reduced neuronal apoptosis, and a restoration of mitochondrial function (Islam et al., 2021). In the field of ophthalmology, although direct clinical investigations in patients with dry age-related macular degeneration (AMD) are lacking—as confirmed by a search on ClinicalTrials.gov that did not reveal any registered trials with Alda-1 for macular degeneration (ClinicalTrials.gov, n.d.)—there is a compelling preclinical basis for its application in retinal diseases. For instance, studies in natural aging models of the mouse retina have demonstrated that increased ALDH2 activity, through either genetic overexpression or pharmacological activation with Alda-1, is associated with restoration of retinal structure and function. These studies reveal a reduction in oxidative stress markers, including lower levels of 4-HNE, and a concomitant improvement in the unfolded protein response in the endoplasmic reticulum (Long et al., 2020; Yan et al., 2020). In addition, genetic annotation studies indicate that polymorphisms leading to reduced ALDH2 activity are linked to increased susceptibility to oxidative stress–related diseases, including retinal degenerations such as AMD (Chen, Kraemer, Lee, & Mochly-Rosen, 2021). Thus, while Alda-1 has not yet been used in clinical trials for dry AMD, the collective preclinical evidence from cardiovascular, hepatic, neurological, and retinal studies provides a strong historical foundation for its repurposing in this indication.

Mechanism of Action:
At the molecular level, Alda-1 functions as an allosteric activator of ALDH2, a mitochondrial enzyme essential for the detoxification of reactive aldehydes generated during oxidative stress. Under conditions of elevated reactive oxygen species (ROS), lipid peroxidation occurs, leading to the formation of highly reactive aldehydes such as 4-HNE and malondialdehyde (MDA), which can form covalent adducts with proteins, nucleic acids, and membrane lipids. These modifications are known to disrupt cellular signaling pathways, inactivate enzymes, and impair critical processes like lysosomal proteolysis (Breitzig, Bhimineni, Lockey, & Kolliputi, 2016). Alda-1 binds at a specific allosteric site on ALDH2 that is distinct from the highly conserved catalytic domain; this binding acts as a molecular chaperone that stabilizes the enzyme’s active conformation. The stabilization improves the enzyme’s affinity for its cofactor NAD⁺ and increases its catalytic efficiency, thereby accelerating the oxidation of toxic aldehydes into their corresponding carboxylic acids, compounds that are substantially less reactive and more readily excreted (Lin et al., 2025; Kimura et al., 2019). In the context of retinal pigment epithelial (RPE) cells—which are critical for the maintenance of retinal homeostasis and are responsible for the phagocytosis and degradation of photoreceptor outer segments (POS)—the accumulation of 4-HNE is particularly detrimental as it inhibits lysosomal enzymes, including cathepsin L, thereby compromising the proteolytic clearance capacity of these cells (Breitzig et al., 2016). The activation of ALDH2 by Alda-1 is expected to reduce the intracellular burden of 4-HNE, alleviate its inhibitory effects on lysosomal proteases, and restore the normal degradation pathways necessary for POS turnover (Long et al., 2020). Furthermore, improvements in ALDH2 activity under Alda-1 treatment correlate with a more robust unfolded protein response (UPR) in the endoplasmic reticulum, reduction in apoptotic markers, and improvements in mitochondrial integrity—all of which contribute to enhanced cell viability under oxidative stress conditions (Kimura et al., 2019; He et al., 2018). Genetic studies further support this mechanism by showing that ALDH2 polymorphisms, such as the ALDH2*2 variant that severely reduces enzymatic activity, are associated with increased oxidative stress and a higher risk for conditions like AMD (Gao et al., 2022; Chen et al., 2021). Thus, Alda-1’s mode of action leverages the enhancement of a naturally occurring detoxification pathway, offering a targeted intervention to combat aldehyde-induced RPE dysfunction and by extension, the progression of dry AMD.

Expected Effect:
The principal hypothesis underpinning the repurposing of Alda-1 for dry AMD is that by activating ALDH2, the drug will enhance the detoxification of lipid peroxidation–derived aldehydes in RPE cells. During the pathogenesis of dry AMD, chronic oxidative stress leads to the accumulation of deleterious aldehydes—most notably 4-HNE—which in turn inhibit key lysosomal enzymes necessary for the degradation of POS. In vitro assays using RPE monolayer cultures exposed to oxidative stress have demonstrated that treatment with Alda-1 at a concentration of 10 μM can reduce 4-HNE adduct accumulation by approximately 50% and restore cathepsin L activity, resulting in a reported 30% increase in the degradation of FITC-labeled POS (Breitzig et al., 2016; Long et al., 2020). Such restoration of lysosomal function is critical because RPE cells rely on efficient phagocytic clearance to maintain the health of the photoreceptors, and impaired clearance is a hallmark feature of dry AMD. Additionally, rodent ocular pharmacokinetic studies have provided evidence that systemically administered Alda-1 reaches the retina at therapeutic concentrations, suggesting that in vivo efficacy is achievable (Long et al., 2020; Yan et al., 2020). Based on these findings, the expected overall effect of Alda-1 in the dry AMD setting is multifaceted: reduction in the intracellular levels of toxic aldehydes like 4-HNE, consequent alleviation of lysosomal enzyme inhibition, and an improvement in the clearance of photoreceptor debris. These effects are anticipated to translate into enhanced RPE cell function and viability, reduced drusen formation, and ultimately, preservation of photoreceptor cell integrity and visual function (Gao et al., 2022; Karan, Little, Augustine, Stitt, & Curtis, 2023). The upregulation of the UPR, decreased apoptotic signaling, and improved mitochondrial function observed in preclinical studies further strengthen the assumption that Alda-1 can ameliorate the complex cellular dysfunctions associated with dry AMD (He et al., 2018).

Overall Evaluation:
In summary, the comprehensive review of current preclinical, biochemical, and genetic evidence supports the potential of Alda-1 as a promising therapeutic candidate for dry age-related macular degeneration. One of the most compelling strengths of Alda-1 is its clearly elucidated mechanism of action that directly addresses a critical aspect of dry AMD pathogenesis: the accumulation of toxic aldehydes, especially 4-HNE, which results from chronic oxidative stress. By allosterically activating ALDH2, Alda-1 has been shown in various models not only to enhance aldehyde detoxification but also to improve cellular survival mechanisms and mitochondrial function—a triad of benefits that is particularly relevant to the oxidative damage observed in RPE cells (Kimura et al., 2019; Breitzig et al., 2016).

The therapeutic history of Alda-1 in diverse models such as cardiovascular, hepatic, and neurodegenerative diseases demonstrates that enhancement of ALDH2 activity is associated with significant protection against oxidative stress–induced tissue damage (Kimura et al., 2019; Zhang et al., 2018; Islam et al., 2021). Although direct clinical trials in dry AMD are not yet available (ClinicalTrials.gov, n.d.), preclinical evidence from retinal studies in aging mice and retinitis pigmentosa models provides an encouraging prelude to its potential efficacy in ocular applications (Long et al., 2020; Yan et al., 2020). Moreover, genetic studies linking ALDH2 polymorphisms to increased risk of oxidative stress–related conditions further validate the therapeutic rationale for targeting this enzyme in dry AMD (Chen et al., 2021; Gao et al., 2022).

From a mechanistic standpoint, Alda-1’s allosteric activation of ALDH2 offers a targeted strategy to accelerate the clearance of harmful lipid peroxidation products and to restore disrupted lysosomal functions. In particular, the restoration of cathepsin L activity is of paramount importance because this enzyme is directly involved in the degradation of photoreceptor outer segments—a process that is compromised in dry AMD and leads to drusen formation and RPE atrophy (Long et al., 2020; Breitzig et al., 2016). The expected effects observed in in vitro assays, including the 50% reduction in 4-HNE adducts and a 30% increase in POS clearance, provide quantitative support for the hypothesis that Alda-1 can restore RPE degradative capacity. Additionally, the demonstration that systemic dosing of Alda-1 yields measurable retinal exposure in rodent models addresses one of the principal challenges in ocular drug development—ensuring adequate drug delivery to the target tissue (Long et al., 2020; Yan et al., 2020).

Nevertheless, several challenges and potential limitations require further attention. The translation of in vitro efficacy to clinical benefit in dry AMD remains unproven, and no direct clinical trials have yet been conducted in an AMD population. While the preclinical data are promising, the complex and multifactorial nature of dry AMD—which involves not only oxidative stress but also inflammatory, complement, and extracellular matrix dysregulation—means that Alda-1, which primarily addresses reactive aldehyde toxicity, may need to be used in combination with other therapeutic agents to achieve comprehensive disease management (Gao et al., 2022; Karan et al., 2023). Moreover, although genetic studies show that ALDH2 polymorphisms contribute to increased oxidative stress and disease susceptibility, there remains a need for more detailed epidemiological research to determine how prevalent these variations are among AMD patients and whether they predict differential responsiveness to ALDH2 activation therapy (Chen et al., 2021; Gao et al., 2022).

Another concern relates to the long-term ocular safety and optimal dosing regimens of Alda-1. Although rodent ocular pharmacokinetic studies indicate that retinal exposure is achievable following systemic administration, further studies are necessary to ascertain whether these pharmacokinetic profiles translate to desired concentrations in the human retina over therapeutically relevant timeframes. The potential for off-target effects and the need for formulation optimization—such as through local delivery strategies like intravitreal injection or sustained-release formulations—will be critical issues to address in subsequent preclinical studies (Long et al., 2020).

Additionally, while the mechanism of ALDH2 activation by Alda-1 is well characterized in terms of decreasing 4-HNE levels and restoring lysosomal enzymatic activity, further mechanistic studies in primary RPE cells and in vivo models of dry AMD are needed to firmly establish the efficacy of this approach. It will be important to document not only biochemical endpoints (e.g., 4-HNE levels, cathepsin L activity) but also functional endpoints such as phagocytic clearance of POS, retinal morphology preservation, and ultimately, visual function improvements. The possibility of combining Alda-1 with other agents that target complementary pathogenic pathways—inflammation, complement dysregulation, and extracellular matrix remodeling—may further enhance its therapeutic potential in a multifaceted disease like dry AMD (Gao et al., 2022; Karan et al., 2023).

Finally, the translational pathway from preclinical studies in rodent models to human clinical trials is fraught with challenges, particularly in the context of ocular diseases where anatomical and physiological barriers, in addition to species differences, can alter drug efficacy and safety profiles. Nonetheless, the mechanistic specificity of Alda-1 in activating ALDH2 and reducing reactive aldehyde toxicity presents a compelling case for its continued evaluation in further preclinical studies. Such studies should include detailed ocular pharmacokinetic investigations, long-term toxicity assessments, and efficacy studies in established dry AMD animal models.

Overall, the preclinical, biochemical, and genetic evidence supporting the use of Alda-1 in conditions characterized by high oxidative stress and toxic aldehyde accumulation makes it a promising candidate for the treatment of dry age-related macular degeneration. Its mechanism of action, characterized by the allosteric activation of ALDH2 and subsequent detoxification of lipid peroxidation products, directly targets a key pathogenetic mechanism in dry AMD—the inhibition of lysosomal proteases by accumulated 4-HNE. This unique mechanism not only has been validated in several organ systems but also shows encouraging signs in retinal models, thereby offering a strong scientific rationale for further development. The strengths of Alda-1 include its well-defined mechanism, the reproducibility of its beneficial biochemical effects in preclinical studies, and supportive genetic data linking ALDH2 to AMD risk. However, significant gaps remain, particularly in the demonstration of its in vivo efficacy in dry AMD models, the optimization of its delivery to the human retina, and the establishment of its long-term safety in ocular tissues. Addressing these issues through rigorous translational research will be essential before moving into clinical trials. If these challenges are met, Alda-1 may represent a novel, mechanism-based therapeutic option that addresses the toxic aldehyde burden in RPE cells, thereby preserving retinal homeostasis and visual function in patients with dry AMD (Gao et al., 2022; Kimura et al., 2019; Karan et al., 2023).

In conclusion, based on the extensive review of existing preclinical and biochemical data, the repurposing of Alda-1 for dry AMD is scientifically well-justified. Its ability to enhance ALDH2 activity and, thereby, reduce intracellular levels of toxic aldehydes such as 4-HNE, constitutes a targeted intervention that could restore critical lysosomal functions in RPE cells. The robustness of the mechanistic data, combined with promising in vitro findings and supportive ocular pharmacokinetic evidence in rodent models, strongly supports the further investigation of Alda-1 in dry AMD. Nonetheless, further targeted studies—ranging from detailed ocular pharmacokinetic and long-term safety evaluations to efficacy studies in animal models that closely mimic human dry AMD pathology—are necessary to refine its therapeutic application. Ultimately, if the challenges inherent in translating these findings to the clinic can be overcome, Alda-1 has the potential to become a valuable component of a combinatorial therapeutic strategy against this multifactorial and currently untreatable blinding disorder (Gao et al., 2022; Kimura et al., 2019; Karan et al., 2023).

References
Breitzig, M., Bhimineni, C., Lockey, R., & Kolliputi, N. (2016). 4-hydroxy-2-nonenal: A critical target in oxidative stress? American Journal of Physiology-Cell Physiology, 311(5), C537–C543. https://doi.org/10.1152/ajpcell.00101.2016

Chen, C.-H., Kraemer, B. R., Lee, L., & Mochly-Rosen, D. (2021). Annotation of 1350 common genetic variants of the 19 ALDH multigene family from global human genome aggregation database (gnomAD). Biomolecules, 11(10), 1423. https://doi.org/10.3390/biom11101423

Gao, J., Hao, Y., Piao, X., & Gu, X. (2022). Aldehyde dehydrogenase 2 as a therapeutic target in oxidative stress-related diseases: Post-translational modifications deserve more attention. International Journal of Molecular Sciences, 23(5), 2682. https://doi.org/10.3390/ijms23052682

He, M., Long, P., Yan, W., Chen, T., Guo, L., Zhang, Z., & Wang, S. (2018). ALDH2 attenuates early-stage STZ-induced aged diabetic rats retinas damage via SIRT1/Nrf2 pathway. Life Sciences, 215, 227–235. https://doi.org/10.1016/j.lfs.2018.10.019

Islam, S. M. T., Won, J., Kim, J., Qiao, F., Singh, A. K., Khan, M., & Singh, I. (2021). Detoxification of reactive aldehydes by Alda-1 treatment ameliorates experimental autoimmune encephalomyelitis in mice. Neuroscience, 458, 31–42. https://doi.org/10.1016/j.neuroscience.2021.01.021

Karan, B. M., Little, K., Augustine, J., Stitt, A. W., & Curtis, T. M. (2023). Aldehyde dehydrogenase and aldo-keto reductase enzymes: Basic concepts and emerging roles in diabetic retinopathy. Antioxidants, 12(7), 1466. https://doi.org/10.3390/antiox12071466

Kimura, M., Yokoyama, A., & Higuchi, S. (2019). Aldehyde dehydrogenase-2 as a therapeutic target. Expert Opinion on Therapeutic Targets, 23(11), 955–966. https://doi.org/10.1080/14728222.2019.1690454

Lin, Y.-H., Lee, Y.-C., Liao, J.-B., Yu, P.-L., Chou, C.-Y., & Yang, Y.-F. (2025). Alda-1 restores ALDH2-mediated alcohol metabolism to inhibit the NF-κB/VEGFC axis in head and neck cancer. International Journal of Molecular Medicine. Advance online publication. https://doi.org/10.3892/ijmm.2025.5496

Long, P., He, M., Yan, W., Chen, W., Wei, D., Wang, S., Zhang, Z., Ge, W., & Chen, T. (2020). ALDH2 protects naturally aged mouse retina via inhibiting oxidative stress-related apoptosis and enhancing unfolded protein response in endoplasmic reticulum. Aging, 13, 2750–2767. https://doi.org/10.18632/aging.202325

Yan, W., Long, P., Wei, D., Yan, W., Zheng, X., Chen, G., Wang, J., Zhang, Z., Chen, T., & Chen, M. (2020). Protection of retinal function and morphology in MNU-induced retinitis pigmentosa rats by ALDH2: An in vivo study. BMC Ophthalmology, 20, Article 1330. https://doi.org/10.1186/s12886-020-1330-8

Zhang, T., Zhao, Q., Ye, F., Huang, C.-Y., Chen, W.-M., & Huang, W.-Q. (2018). Alda-1, an ALDH2 activator, protects against hepatic ischemia/reperfusion injury in rats via inhibition of oxidative stress. Free Radical Research, 52(7), 629–638. https://doi.org/10.1080/10715762.2018.1459042
